Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis: < em > lessons from treatment in adults and the way forward < /em >

Expert Rev Clin Immunol. 2024 Jan 8. doi: 10.1080/1744666X.2024.2303340. Online ahead of print.ABSTRACTINTRODUCTION: Targeting IL-17A using Secukinumab; a humanized monoclonal immunoglobulin G1 (IgG1)/κ against IL-17A is a therapeutic option for immune-mediated disorders such as psoriasis and ankylosing spondylitis. The US Food and Drug Administration and the European Medicines Agency have approved it for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondylarthritis. Recently it has also been approved for use in children with severe plaque psoriasis, active psoriatic arthritis and enthesitis-related arthritis.AREAS COVERED: This review focuses on the role of Secukinumab in the management of children and adolescents with enthesitis-related arthritis and psoriatic arthritis. We discuss the salient findings of pivotal RCTs and other studies supporting the use of Secukinumab in adults and children, in particular, focusing on its safety and efficacy.EXPERT OPINION: Secukinumab is a therapeutic target for psoriasis, psoriatic arthritis and spondyloarthropathies in both adults and children. No major safety signals are observed with its use in short-term follow-up. Thus far, Secukinumab has not been found to significantly increase the risk of tuberculosis (TB).PMID:38186357 | DOI:10.1080/1744666X.2024.2303340
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research